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Abstract
Primary biliary cirrhosis (PBC) is a cholestatic liver disease characterised by the autoimmune destruction of the small
intrahepatic bile ducts. The disease has an unpredictable clinical course, but may progress to fibrosis and cirrhosis.
Although medical treatment with urseodeoxycholic acid is largely successful, some patients may progress to liver
failure requiring liver transplantation. PBC is characterised by the presence of disease specific anti-mitochondrial
(AMA) antibodies, which are pathognomonic for PBC development. The disease demonstrates an overwhelming
female preponderance and virtually all women with PBC present in middle age. The reasons for this are unknown;
however several environmental and immunological factors may be involved. As the immune systems ages, it
become less self tolerant, and mounts a weaker response to pathogens, possibly leading to cross reactivity or
molecular mimicry. Some individuals display immunological changes which encourage the development of
autoimmune disease. Risk factors implicated in PBC include recurrent urinary tract infection in females, as well as
an increased prevalence of reproductive complications. These risk factors may work in concert with and possibly
even accelerate, immune system ageing, contributing to PBC development. This review will examine the changes
that occur in the immune system with ageing, paying particular attention to those changes which contribute to
the development of autoimmune disease with increasing age. The review also discusses risk factors which may
account for the increased female predominance of PBC, such as recurrent UTI and oestrogens.
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Introduction
Primary Biliary Cirrhosis: a disease of Women
Primary biliary cirrhosis (PBC) is a chronic cholestatic
liver disease of autoimmune origin, characterised by
inflammatory destruction of the small intrahepatic bile
ducts, and fibrosis which can progress to cirrhosis and
subsequent liver failure [1-3]. Symptoms include fatigue,
insomnia, pruritus, Sicca symptoms, and arthralgias.
More severe symptoms relate to portal hypertension and
hepatic decompensation [1-3]. PBC shows a high female
preponderance, mainly affecting middle aged women
[1-4]. The female to male ratio ranges from 9:1 to 20:1,
which is relatively higher than other autoimmune dis-
eases [2]. Diagnosis requires the presence of at least two
out of three of the following: antimitochondrial antibo-
dies (AMA) in serum, biochemical markers of cholesta-
sis, and characteristic histopathological features [2,5-7].
AMA and disease-specific anti-nuclear antibodies
(ANA) are usually present at high titres [2,5,6,8]. Many
‘non-autoimmune’ liver disorders such as viral hepati-
tides and acute liver failure are characterised by the pre-
sence of autoantibodies, however, when AMA are
present they are often suggestive of co-existing PBC
[6,9-18]. In these non-autoimmune driven liver patholo-
gies, it is not clear whether AMA or other autoantibo-
dies just indicate immune dysregulation or are
pathologically relevant [19-25].
AMA are present in 95% of PBC patients, with a spe-
cificity of nearly 100% [6,7,20,21,26,27], therefore true
AMA-negative PBC can exist but is extremely rare [28].
AMA is primarily of the IgG isotype, however, IgA and
IgM are also detected [5]. As the presence of AMA is so
strongly associated with PBC, it is generally viewed that
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tually develop PBC [29,30]. Patients with PBC exhibit a
multi-lineage response to the E2 subunit of the pyruvate
dehydrogenase complex (PDC-E2), which involves AMA
as well as autoreactive CD4 and CD8 responses
[6,31-33]. Histological features typical for PBC include:
destruction of biliary epithelial cells (BEC), loss of small
bile ducts (ductopaenia) with portal inflammatory cell
infiltration; and occasional granuloma formation
[1-3,34]. The portal inflammation is comprised largely
of CD4, CD8, and B cells, as characterised by immuno-
histochemistry [2,33,35].
PBC: A disease of the old
PBC is overwhelmingly a disease of middle-aged and
older females, and is virtually absent in the paediatric or
adolescent population, although several case reports
indicate the development of PBC in children [23,36-41].
On closer analysis, these cases rarely represent true (or
confirmed) PBC, with several of these cases representing
AMA positivity in the absence of clinical evidence of
disease [41], or AMA positivity in the presence of liver
disease other than PBC [23,38]. Other cases represent
PBC-like disease, which result from genetic mutations in
genes controlling immunological regulation [36,40]. For
example, Aoki and colleague report the case of a six
month old male with abnormal liver biochemistry, and
AMA positivity [36]. Histology in that case was not
characteristic of PBC and the child was eventually diag-
nosed with IL-2-receptor- alpha deficiency, which
resulted in defects of T regulatory cells [36]. This is
similar to another case report by Tsuda and colleagues,
who noted AMA positivity in an 11 year old with IPEX
syndrome, a congenital disorder of immune regulation
[40]. Although AMA positivity is viewed as being pre-
dictive of eventual PBC development in adults, it is
unclear as to whether this applies in the paediatric
population.
Only two case reports indicate genuine cases of pae-
diatric PBC. Melegh et al [39] notes the case of a six
year old female with AMA positivity and histological
features of PBC, which progressed to fibrosis. The AMA
reactivity in that case was atypical to most PBC cases, in
that specificity was to PDC-E3 related subunit as well as
anti-citrate synthase [39]. Dahlan and colleagues report
PBC in two children, one at eleven years, and the other
at 15 years [37]. Follow-up of the eleven year old
showed that she progressed from stage II PBC at 16
years, to stage IV PBC at 21 years of age, when she was
transplanted [37]. Interestingly, her 30 year old mother
also had PBC. In summary, true paediatric PBC is
exceedingly rare, and likely represents an aetiopathogen-
esis which is highly atypical compared to most cases of
PBC.
Why is PBC a disease of older women?
Although the aetiopathogenesis of autoimmune gastro-
intestinal and liver diseases remains poorly understood,
it is believed that genetic susceptibility, immune dysre-
gulation and exposure to environmental triggers are
responsible for antigen-specific immunological break-
down that lead to the development of the disease
[22,42-51]. The exact mechanisms by which environ-
mental agents can trigger immunological breakdown are
not well defined, but in most cases self/non-self mimicry
has been considered to be instrumental [52-60]. Various
environmental triggers have been implicated in the
development of PBC, including xenobiotics, infectious
agents, and hormones [49,52,61-71], but why PBC pri-
marily affects women in their fifth or sixth decade is
still unanswered.
This review will address the current evidence sur-
rounding the high female preponderance of PBC within
a particular age group. Current evidence relating to the
ageing immune system suggests an increased risk of
developing autoimmune disease in later life (Table 1). In
addition, risk factors for PBC, such as recurrent urinary
tract infections (UTI), reproductive history and oestro-
gen deficiency, appear to increase the susceptibility
towards disease development in females (Table 2).
The ageing immune system and impaired regulatory
mechanisms
Out of all autoimmune diseases, PBC has one of the lat-
est ages of onset, followed by systemic sclerosis and
Sjogren’s syndrome [72]. Intriguingly, Sjogren’ss y n -
drome (and to a lesser extent systemic sclerosis) co-
exist in a significant proportion of patients with PBC.
This raises the question as to what role ‘immunosenes-
cence’, the term used to describe the ageing of the
immune system, plays a role in the pathogenesis of
these diseases. Immunosenescence begins in approxi-
mately the fifth or sixth decade of life, and is charac-
terised by an age dependant, progressive decline in
immunological functioning [72,73]. Immunological
changes implicated in the development of immunose-
nescence include cumulative alterations in B and T cell
populations, increased levels of memory cells producing
Th1 and 2 cytokines and T cell dysfunction due to thy-
mic degeneration [73,74]. It has been suggested that thy-
mic degeneration with age may lead to an accumulation
of T cells that are reactive to neo(auto)antigens [74] and
therefore increase the likelihood of a breakdown in self
tolerance, as well as susceptibility to disease-triggering
infections.
Though the total T cell number does not appear to be
significantly decreased with age, there is an alteration of
T-cell receptor (TCR) signalling, as well as TCR re-
expression, namely due to decreased CD28 expression
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gen-mediated T cell activation, proliferation and survival
[76-78]. Virtually all naive T cells in the umbilical cord
are CD28+ [79]. So called CD28 null cells (CD28-),
which do not express the CD28 receptor, are function-
ally active oligoclonal lymphocytes that lack proliferative
capacity, have reduced antigen receptor diversity and
defective antigen induced proliferation hence are senes-
cent cells [76,78]. It has emerged that the accumulation
of CD28- cells occurs consistently with age, and CD28-
T cells are predictive of immune system incompetence
in the elderly [76,78]. By the age of 80, 10-15% of per-
ipheral blood CD4+ and 50-60% CD8+ T cells lack
CD28 [78]. Increased CD28- cell accumulation is
associated with a reduced response to pathogens and
vaccines [76,78], which is reflected in the low response
to the influenza virus in the elderly [80]. In addition,
CD28- cells have been found in patients with chronic
inflammatory syndromes of all age groups, indicating a
premature senescence of lymphocytes due to persistent
immune activation [76,78]. Repeated stimulation of puri-
fied CD28+ cells with a specific antibody to the T cell
receptor (TCR)/CD3 complex, results in decreased
CD28 expression, and an increased proportion of CD28-
cells [76]. Increased stimulation with IL-15 and TNF-a
h a sa l s ob e e ns h o w nt oa u g m e n tt h el o s so fC D 2 8[ 7 8 ] .
The loss of CD28 is therefore characteristic of both age-
ing, as well as chronic inflammatory disease. CD8
Table 1 Features of immunological ageing seen in the cellular pathology of primary biliary cirrhosis (PBC).
Ageing Feature Presence in PBC
Decreased regulatory T cell
(Treg) response
- Increased CD127 and decreased CD39 on CD8+ T cells
-CD8+CD28- cells fail to display a regulatory response when incubated with IL-10
Decreased telomere length -Quantitative fluorescence in situ hybridisation has shown decreased telomere length in biliary epithelial cells
(BEC) of primary biliary cirrhosis (PBC) patients
DNA damage - gammaH2AX-DNA-damage-foci detected in BEC
Increased apoptosis -Apoptotic marker Bcl-2 in BEC (may increase PDC-E2 exposure)
-Increased apoptotic marker CD95 (Fas) on BEC
-Unmodified PDC-E2 found in apoptotic blebs (apotopes) in BEC
Increased cellular senescence -Increased expression of senescence markers p16 and p21 in BEC
-Decreased Ki67 expression in BEC, indicating decreased cellular proliferation
-Decreased Bmi-1 (senescence regulator) expression in BEC
Increased autophagy -Increased LC3 expression in BEC, which correlated with increased autophagy
Several features characterise an aged immune system, including changes in T cell response, decreased telomere length and DNA damage, as well as apoptosis
and cellular senescence. These features have also been demonstrated in liver tissues from patients with PBC. These findings may, in part, explain why PBC
patients often present in middle age, compared to other autoimmune diseases. Please see relevant sections in the text for more detailed descriptions.
Table 2 PBC risk factors associated with female sex and ageing
Female Risk Factor Significance
Recurrent urinary tract infections Molecular mimicry and cross reactivity with bacterial (such as E. coli) peptides and PDC-E2
epitopes
Oestrogen deficiency Increased propensity towards ductopaenia
Increased incidence of vaginal infections Alterations in vaginal flora increase the risk of developing urinary tract infections, which
appear to play a role in PBC
Ageing Risk Factors Significance
T cell membrane rigidity and decreased cell membrane
fluidity
Alterations in T cell receptor signalling
Decreased CD28 expression (especially in CD8+ cells) Reduced regulatory T cell function and reduced immune response to infections
Phenotypical alterations in CD8+ cells (such as
increased CD127, and decreased CD39)
Decreased T regulatory cell function
Increased telomere shortening from oxidative stress an
ongoing inflammation
Increased cellular senescence, autophagy and apoptosis
Increased senescence and autophagy May contribute to exposure of self antigens to the immune system, as well as contributing
to a pro-fibrotic and pro-inflammatory environment
Increased apoptosis Formation of apoptotic blebs (apotopes) increase exposure of mitochondrial antigens to
the immune system
Several risk factors related to female sex and increased age appear to be significant in the pathogenesis of primary biliary cirrhosis (PBC). Risks associated with
females include recurrent urinary tract infections, oestrogen deficiency, and increased incidence of vaginal infections. Age related changes (which may increase
risk for PBC development) include alterations in regulatory T cell function, increased senescence and autophagy, as well as apoptosis.
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immune disease, and their increased effector functions
may enhance autoimmune disease and inflammatory
responses [78]. CD8+CD28- T cells accumulate due to
normal ageing, but also reflect chronic infection with
viruses such as Epstein-Barr virus, human immunodefi-
ciency virus, and human cytomegalovirus [78,81]. The
loss of immunological tolerance and increased suscept-
ibility to infections is interesting in the case of PBC, as
numerous infectious agents have been implicated in the
immunopathogenesis of PBC, by mechanisms such as
molecular mimicry and immunological cross-reactivity
[47,58,62,82-91].
The changes noted above have not been specifically
linked to PBC, but do give a general view of immunolo-
gical alterations which may contribute to autoimmunity
as we progress in age (Table 1). However, several phe-
notypic and functional changes have been noted in the
CD4 and CD8 population of PBC patients [92]. As men-
tioned, PBC is histologically characterised by a dense
mononuclear cell infiltrate, populated largely by CD4
and CD8 T lymphocytes [1-3,34]. Additionally, higher
numbers of CD4 and CD8 T lymphocytes are found in
the liver than in the peripheral circulation of PBC
patients [92]. This has led to the suggestion that CD8+
cells may mediate BEC damage [92]. Bernuzzi and col-
leagues examined CD8 T regulatory (Treg) cells in PBC
patients, and found several phenotypic and functional
alternations [92]. Phenotypically, CD8 Treg from PBC
patients had increased CD127 and reduced CD39
expression [92]. As CD127 is a marker of effector func-
tion whilst CD39 is indicative of normal Treg function,
this abnormal phenotype may be indicative of a failure
of competent Treg functioning [92]. There was no sig-
nificant difference noted in the number of CD8+CD28-
cells in PBC patients versus controls, however, CD8
+CD28- cells from PBC patients failed to exhibit a regu-
latory immune response after incubation with IL-10
[92]. Interestingly, CD4+CD25+ function was not altered
in PBC, which differs from other autoimmune disease
[92]. These data indicate that alterations in CD8+Treg
and failure of regulatory mechanisms are a feature of
PBC.
Telomere and Telomerase activity is altered in ageing and
in PBC
Telomeres are located at the ends of chromosomes, are
composed of repeated DNA sequences and ensure that
each DNA replication cycle has been completed [93].
With each division, sequences of the telomeres are lost,
forming the basis for the hypothesis that telomere short-
ening occurs with age. Moreover, the loss of telomere
sequences can be accelerated through oxidative stress
and inflammation [93]. Short or damaged telomeres
may induce DNA breaks, initiate cell senescence, or
induce apoptosis [93]. Senescence occurs at a particular
telomere length, at which point the cell passes the so
called ‘mortality checkpoint 1’, which is under control of
p53 and Rb genes [93]. Further loss of telomere length
and passage through mortality checkpoint 2, will induce
apoptosis [93]. These events could in turn result in a
loss of immunological tolerance [93] and it has been
observed that shortened telomere length is a feature of
many autoimmune diseases [94-103] including PBC
[104]. Of note, increased disease activity has been corre-
lated with increased telomere shortening in systemic
lupus erythematosus (SLE) [103].
Telomerase is an enzyme which prevents telomere
shortening, and may also increase telomere length [93].
Telomerase activity varies among autoimmune diseases
[93], for example, there is increased telomerase activity
in SLE [105], RA [106], juvenile idiopathic arthritis [107]
and adult onset still disease [108], whilst telomerase
activity is unchanged in Wegener’s granulomatosis
[109], and even reduced in systemic sclerosis [106].
Shortened telomere length with associated cellular
senescence has been well demonstrated in a study by
Sasaki and colleagues [104]. In that study, the BEC telo-
mere length of 13 PBC patients, as well as 13 control
subjects (consisting of liver samples from healthy patients
and chronic viral hepatitis), was examined using quanti-
tative fluorescent in situ hybridisation [104]. In addition,
immunohistochemical studies for the senescence markers
p16INK4a and p21WAF/Cip1, as well as for DNA
damage, were performed [104]. A significant decrease in
telomere length was noted in damaged BEC from PBC
patients, in comparison to histologically normal BEC in
PBC patients and controls [104]. Immunohistochemistry
demonstrated gH2AX-DNA damaged foci in BEC of PBC
patients, with cellular senescence confirmed by positive
p16INK4a and p21WAF/Cip1 staining [104]. These
changes were not observed in healthy or pathological
controls, and suggest that telomere shortening with asso-
ciated DNA damage and cellular senescence is a unique
feature of damaged BEC in PBC [104]. It should be noted
that it was not possible to correlate telomere length with
age, due to the small cohort size and telomerase activity
was not examined. Further confirmatory studies using a
larger cohort, as well as an analysis of telomerase activity
in the BEC of PBC patients is warranted.
Senescence and autophagy
Senescence is a delayed stress response, which is
induced by factors such as telomere shortening, oxida-
tive stress, and DNA damage [110,111]. Senescence may
also be induced by ageing cells, as a mechanism for lim-
iting the depletion of cells in ageing tissue [110]. Several
studies have demonstrated that oxidative stress is an
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[104,112-114]. Sasaki et al [112] notes that cellular
senescence in early-stage PBC was associated with an
infiltration of myeloperoxidase-positive inflammatory
cells, indicating oxidative stress. In that study, BEC
showed increased p21WAF/Cip1 staining, and decreased
Ki67 (a marker of proliferating cells) staining [112].
Another study by the same group examined the expres-
sion of the Bmi1 gene (which suppresses p16INK4a
activity) in liver samples from 18 PBC cases, 19 patholo-
gical controls, and 16 healthy livers [114]. Bmi1 was sig-
nificantly reduced in damaged BEC of PBC patients,
compared to strong expression in the nuclei of control
groups [114]. In addition, cultured mouse BEC subjected
to oxidative stress from H2O2 exposure had significantly
decreased Bmi1 expression, and increased p16INK4a
activity [114].
Senescence is of interest in the development of PBC
for several reasons. Firstly, senescent cells promote an
environment which is pro-inflammatory and pro-fibrotic
through secretion of cytokines (such as IL-1 and IL-6)
and chemokines (IL-8 and MCP-1) [46,111,115-118].
Secondly, the process of autophagy, or “self eating”,i s
involved in the maintenance of senescence, and may
provide a route for BEC damage, as well as exposure of
autoantigens into an established inflammatory environ-
ment [111,117,119]. Autophagy is a process whereby
intracellular proteins and organelles are degraded to
suppress damage and maintain metabolism of senescent
cells [120-123]. An immunohistochemical study by
Sasaki and colleagues investigated whether autophagy
was associated with senescence in PBC [119]. Liver sam-
ples from 37 PBC and 75 controls were stained for
autophagy markers LC3, cathepsin-D, and LAMP-1, as
well as for senescence markers p16INK4a and p21WAF/
Cip1 [119]. LC3 expression was present in 90.5% of
inflamed and 27.5% non-inflamed bile ducts of PBC
patients [119]. LC3 also co-localised with cathepsin-D,
LAMP-1, p16INK4a and p21WAF/Cip1 [119]. These
findings were not observed in the control group. Cul-
tured BEC subjected to oxidative stress (with hydrogen
peroxide), DNA damage (with Etoposide), and serum
deprivation, induced cellular senescence [119]. Inhibiting
autophagy with 3-methyladenine also reduced stress
induced senescence, including a reduction of senescence
associated phenotype markers CCL2 and CX3CL1 [119].
A l t h o u g hs e n e s c e n c ea n da u t o p h a g ym a yp l a yar o l ei n
BEC damage and exposure of cryptic epitopes, the com-
petitive process of apoptosis may also be implicated in
the pathogenesis of PBC.
Apoptosis: potential source of autoantigens
Alterations in the apoptotic process in PBC may provide
a source for BEC autoantigens, as well as limiting the
immune systems ability to clear infections. Cell shrink-
age, chromatin condensation, DNA cleavage, and packa-
ging of cellular material into apoptotic bodies called
blebs are all features of apoptotic cells [124,125]. The
apoptotic process may be initiated as an alternative to
senescence and autophagy, by triggers such as cytotoxic
or oxidative stress, cytokine deprivation, or genomic
damage [124,125]. Apoptotic cells release “find me” sig-
nals such as soluble lysophosphatidylcholine, and “eat
me” signals such as phosphatidylserine [125,126]. These
signals are recognised by phagocytes, which bind the
apoptotic cell [125,126]. Phagocytes which bind the
apoptotic cell release anti-inflammatory cytokines such
as IL-10, and also induce a reduction of inflammatory
c y t o k i n e ss u c ha sI L - 1 b,T N F - a,a n dI L - 1 2
[125,127,128]. Deficiencies in this process may result in
the release of cellular material, which could be pre-
sented by antigen presenting cells to autoreactive B and
T cells, thereby provoking inflammation and autoanti-
body formation [124,125,129-131]. In addition, the
apoptotic blebs appearing on the surface of apoptotic
cells can act as a source of autoantigens [132-138].
Apoptosis has been shown to play a role in several
autoimmune diseases, such as SLE [129-131,139-142]
and PBC [111,132,134-136,142-144]. However, several
unique characteristics are found in the apoptotic pro-
cesses of PBC versus SLE. Lorenz and colleagues note
an increased number of apoptotic peripheral lympho-
cytes from SLE patients in vitro,w h i c hr e l a t e st oa ni n
vivo increase in these cells activation [142]. Increased
numbers of apoptotic cells were found in the skin of
patients with cutaneous lupus, after exposure to UV
light [141], and remnants of apoptotic cells were found
in the germinal centres of lymph nodes in SLE patients
[139]. Additionally, tingible body macrophages, which
clear apoptotic cells in healthy individuals, were noted
to have abnormal morphology in SLE patients [139]. It
was demonstrated by Koga et al [143] that apoptosis is a
feature of BEC in PBC patients. That study involved 35
PBC patients, 16 normal controls, and 17 chronic hepa-
titis C patients [143]. In situ nick-end labelling showed
increased DNA fragmentation in BEC of PBC patients,
and immunohistochemical analysis of Bcl-2 showed that
it was more frequently expressed in the BEC and hepa-
tocytes of PBC patients [143]. Ten of the PBC patients
underwent a second liver biopsy after treatment with
urseodeoxycholic acid, the treatment of choice for PBC,
and it was found that there was decreased Bcl-2 expres-
sion in the BEC, and decreased DNA fragmentation
[143]. Kuroki et al [144] also indicates that the Fas path-
way of apoptosis may be involved in PBC, as BEC
showed increased Fas (CD95) on their cell membranes.
Studies into apoptosic pathways in PBC have also pro-
vided interesting data in regards to why AMA are so
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that the recognition of PDC-E2 still occurred in apopto-
tic BEC. The PDC-E2 was intact, as it had not been
cleaved by caspases [136] and autoantibody recognition
of PDC-E2 was also maintained due to a lack of glu-
tathionylation [136]. Lleo et al [135] found that unmodi-
fied PDC-E2 localised into the apoptotic blebs in human
intrahepatic BEC, called apotopes [135]. Sera from
AMA positive individuals reacted with PDC-E2 on
apoptotic BEC, demonstrating an accessibility of PDC-
E2 to the immune system [135]. The same group of
investigators have also demonstrated that BEC apotopes
in the presence of macrophages from PBC patients, as
well as AMA, induced the production of inflammatory
cytokines [134]. Finally, it has also been demonstrated
that the phagocytosis of apoptotic BEC by BEC provides
these cells with a source of mitochondrial self-peptide
[132].
The studies mentioned so far in this review demon-
strate that immunological changes which occur with age
may promote an increased susceptibility for PBC devel-
opment. Although these changes occur in normal age-
ing, it appears that they may be altered, or even
accelerated in individuals with a genetic predisposition,
or who are exposed to other triggers implicated in PBC
development. Oxidative damage and decreased immuno-
logical tolerance open the door to the suggestion that
infectious agents may also be involved in PBC develop-
ment. Several features of the infectious model underly-
ing PBC development appear to be unique to females,
which may explain the female predominance of PBC.
Recurrent Urinary Tract Infections and E. coli
Several large epidemiological studies have consistently
indicated that recurrent UTIs are a risk factor for PBC
development [61,63,64,145]. The association between
UTI and PBC was first made by investigators at the
Royal Free Hospital in London, who found an increased
rate of bacteriuria in female PBC patients, compared to
controls [89,146]. One study reported recurrent UTI in
19% of PBC patients, compared to 5-6% of controls [89].
57% of patients also reported at least one bacteriuric
episode and more than two episodes were reported in
26% of PBC patients [89]. Parikh-Patel and colleagues
demonstrated a positive association between PBC and
recurrent UTI [63]. A large and comprehensive study by
Gershwin et al [145] demonstrated that 59% of 1032
PBC patients reported UTI. A relatively recent study by
Prince and co-workers [64] also demonstrated an asso-
ciation of PBC with UTI. That study involved one group
of 318 PBC patients from a geographically defined area,
and another involving 2258 patients recruited from a
PBC support group [64]. Multivariate analysis showed
an association between UTI and PBC in PBC patients
from both groups, but not in a cohort of 3936 demogra-
phically matched controls [64].
The link between UTI and PBC has been limited, as it
is unclear as to whether recurrent UTI preceded PBC
diagnosis, or is sequelae of concomitant autoimmune
disease, such as Sjögren’s/Sicca syndrome. It could be
argued that changes in mucosal immunity which occur
in these conditions, increases the risk of developing
UTI. However, a recent study by Varyani and colleagues
[147] has demonstrated that UTI preceded the diagnosis
of PBC in a large cohort of PBC patients. Using the
General Practice Research Database, the investigators
identified 800 PBC patients, 7991 matched controls
from the general population and 12 137 chronic liver
disease control patients [147]. UTI had been diagnosed
within one year prior to PBC diagnosis in 29% of PBC
patients, compared to 22% of matched controls and 17%
of chronic liver disease controls [147]. Within a five
year period prior to diagnosis, 19% of PBC patients had
been diagnosed with UTI, compared to 14% of matched
controls and 11% chronic liver disease controls [147].
Of note, the mean age of PBC diagnosis was 63 years
[147]. Whether PBC patients are more prone to UTI, or
whether the increased incidence of UTI in PBC patients
is due to natural ageing is unknown, as the incidence of
asymptomatic and symptomatic bacteriuria increases
with age [148]. Escherichia coli (E. coli)i st h em o s t
commonly identified organism, being isolated in 85.7%
of male and female UTI patients aged 15-65 years, and
in 74% of patients over 65 years [148].
E. coli has been identified as an organism of interest,
due to its frequency as a causative organism in UTI and
b e i n gi m p l i c a t e di nu pt o7 0 %o fP B Cp a t i e n t sw i t h
recurrent UTI [89]. Early studies have been focused par-
ticularly on rough forms of E. coli and their relation to
PBC [86,89,149]. We and others have investigated the
role of microbial/self molecular mimicry and immunolo-
gical cross-reactivity as a mechanism responsible for the
induction of liver autoimmunity, including that seen in
patients with PBC [54,91,150-160]. Support for the
molecular mimicry hypothesis in PBC has been found
on the experimental level, where sera from PBC patients
react with both E. coli and human PDC-E2 [161]. Inter-
estingly, sera from 52% of patients with PBC reacted
with PDC-E2 in one cohort [162]. Several studies have
noted a cross reactivity between antibodies in PBC
patients with amino acid sequences inside the ATP-
dependant Clp protease of E. coli [86,163,164]. Similar
lipoyl domain sequences are also found between E. coli
and human PDC-E2 and these sequences are essential
for T cell epitope recognition of PDC-E2 in humans and
E. coli [83,91]. The same study found a strong associa-
tion between this reactivity and a history of recurrent
UTI [83]. Shimoda et al provided data clearly
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gues are targets of cross-reactive responses at the CD4
T-cell level [91,165,166]. Of note, these epidemiological
and experimental studies demonstrate a potential link
between two pathologies with a high female
preponderance.
In addition to E. coli, Lactobacillus delbrueckii (L. del-
brueckii)i se m e r g i n ga sa ni m p o r t a n to r g a n i s mi nt h e
link between recurrent UTI and PBC as it may be both
synergistically and directly pathogenic. L. delbrueckii is a
component of normal vaginal flora, and alterations in
this flora may lead to recurrent vaginitis, which in turn
may lead to colonisation by bacteria such as E. coli and
hence recurrent UTIs [167]. Vaginitis and vaginal infec-
tion has also been noted as being more prevalent in
PBC patients [63,145]. It is therefore plausible that L.
delbrueckii contributes to the development of recurrent
UTI, by creating an environment which is prone to
colonisation by bacteria such as E. coli. In addition,
recent studies have also demonstrated that L. delbrueckii
can be a directly pathogenic organism of UTI in elderly
women [168,169].
Lactobacilli have also been linked to PBC development
in a 39 year old female who received several Lactobacilli
vaccinations for recurrent vaginitis [25]. AMA from this
patient reacted against human PDC-E2, and was also
cross reactive with beta-galactosidase of Lactobacillus
delbrueckii [25]. It has been previously identified that L.
delbrueckii contains epitopic regions which mimic PDC-
E2 [167]. Hence, in women, L. delbrueckii may be impli-
cated directly, through molecular mimicry, and indir-
ectly, by predisposing to recurrent UTI in the
pathogenesis of PBC. Several other bacteria, viruses, and
parasites are being investigated as potential triggers of
PBC via molecular mimicry and cross reactivity, but one
in particular, Novosphingobium aromaticivorans,m a y
also be relevant to female preponderance.
Novosphingobium aromaticivorans, oestrogen, and
reproduction
N. aromaticivorans i sag r a mn e g a t i v eb a c t e r i af o u n d
universally in air, soil, and water [170]. Of relevance to
PBC this bacterium contains two proteins which share
amino acid sequences with the immunodominant epi-
tope of PDC-E2 [170]. N. aromaticivorans has also been
found to induce PBC-specific anti-mitochondrial antibo-
dies in immunised mice that develop liver pathology
with histological characteristics similar to that seen in
PBC [171].
Several studies have indirectly alluded to oestrogen
deficiency as a potential risk factor for PBC develop-
ment [61,64,145,172,173] and N. aromaticivorans has
been shown to metabolize xenobiotics and oestrogen
[174]
The intracellular pathways involving the stimulatory
affects of oestrogen on cholangiocyte proliferation has
been investigated by Alvaro and colleagues [174-176].
Animal models have shown that oestrogens and other
growth factors induce cholangiocyte proliferation via
activation of the Src/Shc/ERK molecular signalling cas-
cade [176]. Alvaro and colleagues suggest that there is a
synergistic role between oestrogens and growth factors
in cholangiocyte proliferation [176]. Antagonists to oes-
trogen receptors (OR) also inhibit cholangiocyte prolif-
eration and reduce expression of ERK/Shc [176].
Exogenous oestrogen administration with 17-b-oestra-
diol increases Src/Shc/ERK protein expression as well as
cholangiocyte proliferation in vitro [176]. These results
demonstrate that oestrogens likely play a role in cholan-
giocyte proliferation [174-176].
T h es a m eg r o u po fi n v e s t i g a t o r sa l s od e m o n s t r a t e da
role for oestrogen in the progression of PBC [174]. Liver
biopsies from PBC patients and controls (normal liver,
primary sclerosing cholangitis and alcoholic cirrhosis)
were immunohistochemically examined for oestrogen
receptor alpha (OR-a), oestrogen receptor beta (OR-b),
cytokeratin 19, proliferating cellular nuclear antigen
(PCNA), and Fas by terminal deoxynucleotide transfer-
ase end labelling (TUNEL) [174]. OR-a and OR-b were
only found in PBC samples [174] and OR-b was present
in all histological PBC stages in 50-65% of PBC patients.
OR-a expression varied based on histological stages,
with OR-a being expressed in 1% of those in stage 1,
12% in stage 3, and absent in stage 4 [174]. This corre-
lated with PCNA expression and maximal ductopaenia
[174]. OR-a was significantly decreased in PBC com-
pared to that seen in pathological controls [174]. These
findings suggest that OR-a expression is reduced in
advanced PBC, which favours a progression towards
ductopaenia [2,174]. Interestingly, an early study indi-
cated that exogenous oestrogen administration improved
liver biochemistry in PBC patients [177]. Those
researchers noted a fall in serum enzymes at mid-men-
strual cycle in untreated PBC patients [177]. Five PBC
patients were administered ethinyl oestradiol: 1 preme-
nopausal, 1 post-menopausal, and 3 post-oophorectomy
[177]. Aspartate transaminase decreased by greater than
50% after 2 weeks of treatment in 4 of the 5 patients, g-
GT decreased by 50% in all 5 patients, and alkaline
phosphatase decreased by 30% [177]. Repeated courses
of oestradiol administration produced similar results
[177]. Although this study was limited in terms of con-
trols and cohort size, it is interesting given the more
recent findings indicating the protective effects of oes-
trogen in PBC, as well as a decrease in hormone repla-
cement therapy reported in some studies [64,145].
Apart from oestrogen, several characteristics in the
obstetric histories of women with PBC are worth noting.
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incidence of sexually transmitted infections in female
PBC patients versus controls (18.5% versus 10.4%), as
well as an increase in vaginal infection (63.4% versus
35.2%)[173]. Epidemiological studies have also indicated
that PBC patients tend to be younger at the time of
their first pregnancy, as well as having an increased inci-
dence of pregnancy termination and extrauterine preg-
nancy [61,63,64,145]. Investigation into the reproductive
characteristics of PBC patients therefore warrants
further study.
Viruses and ageing in PBC
Age related changes in the ability of antigen-specific
cellular immune responses to clear viruses have been
noted. This has led to the assumption that ageing as a
risk for autoimmunity may be due to the inability to
erase viral-triggered autoimmune responses [74,75].
Whether this is possible in the case of PBC is still
unknown. Geographical, clinical, and experimental evi-
dence has led to the suggestion that a viral cause may
underline the development of PBC in some individuals
[178,179]. Clusters of PBC have been noted among
individuals who emigrate from areas with low PBC
rates to areas with high PBC rates, and unrelated indi-
viduals living in the same household have developed
the disease [178]. As well, recurrence of PBC after
liver transplantation appears to occur earlier, and with
a greater severity in patients treated with tacrolimus,
and the opposite is observed with cyclosporine admin-
istration [178,180]. The group led by Mason and col-
leagues have found evidence of viral particles in the
biliary epithelial cells of PBC patients, and antibody
reactivity to retroviruses has been found in the sera of
PBC patients [181]. This reactivity was found to be
specific to viral proteins when reactivity to AMA was
blocked out [182]. Genetic material of a human betare-
trovirus (HBRV) (with 95% homology to mouse mam-
mary tumour virus, or MMTV) has been detected in
the lymph nodes of ~75% of PBC patients in a cohort
of PBC patients [183]. Further analysis by immunohis-
tochemistry also demonstrated HBRV material in the
lymph nodes of PBC patients, which was not observed
in controls [183]. However, lower detection rates were
observed when hepatocytes were analyzed (only ~30%),
as well as in other studies utilising a PCR approach
[183,184]. Selmi et al [184] were unable to detect reac-
tivity between PBC sera and a mouse MMTV, and no
immunohistochemical or molecular evidence for
MMTV was found in liver specimens. In contrast to
this, Johal and colleagues found MMTV sequences in
healthy liver tissues, in addition to liver tissue from a
variety of liver diseases including PBC [185]. Selmi
notes that reactivity between PBC sera and some viral
proteins may be due to the presence of mitochondrial
antigens in the viral preparations derived from murine
MMTV [184]. However, the differing rates of viral
detection from one study to the next may be due to
differing methodological approaches [178]. Mason
[178] highlights that studies by his group utilised a
RT-PCR approach, which is more sensitive for detect-
ing retroviral material than PCR which was used in the
study by Selmi [184]. As well, other studies have not
examined lymph node material from PBC patients,
despite these tissues being the major reservoir for
HBRV [178,183]. Lymph nodes co-cultured with nor-
mal cholangiocytes were shown to induce the expres-
sion of AMA-antigens on the cholangiocyte cell
membrane [186]. Another study has demonstrated that
HBRV infected cells expressed the PDC-E2 phenotype,
and in vitro cell cultures were induced to express
PDC-E2 when exposed to HBRV [187]. Of interest, a
randomized controlled trial with anti-retroviral therapy
is planned to treat patients with PBC who are unre-
sponsive to UDCA [178,188,189], although similar stu-
dies [190] have failed to reach non-histological
endpoints utilized in clinical trials in PBC [191].
A viral role in the pathogenesis of PBC is still under
debate [191]. Several factors may account for this, such
as the fact that only a small number of studies have
been performed, as well as the conflicting results gener-
ated by different groups [191]. As well, differences in
experimental approach and design, as well as authors
interpretation of the results, may also account for the
inconclusive status of viruses in the pathogenesis of
PBC [178]. Further studies are needed to provide a con-
clusion in either direction.
Concluding Remarks
Primary biliary cirrhosis is an autoimmune disease with
a striking predominance in middle-aged females. Var-
ious genetic characteristics and environmental factors
have been implicated in the disease development and
progression. Factors, such as recurrent UTI and oestro-
gen signalling provide insight as to why females are
more prone to PBC. Studies characterising the decline
of the immune system with age, have provided evidence
as to why presentation with PBC often occurs in middle
age. It is likely that genetic predisposition combined
with environmental triggers act in a multiple hit model.
T h e s ef a c t o r sm a ya l s oc o n t r i b u t et ot h ed e c l i n eo fa n
already ageing immune system, through recurrent infec-
tions and inflammation, as well as oxidative damage.
The immune system may then reach a critical stage
where tolerance to self is lost. Increased cellular stresses
via environmental or infectious triggers, may also
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which allows for autoepitope exposure to the immune
system.
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